Lv1
66 积分 2022-02-09 加入
THRIVE-2 phase 3 trial of Veligrotug (VRDN-001) in chronic thyroid eye disease (TED): efficacy and safety at 15 weeks
2天前
求助中
Expanding the Potential Treatment of Thyroid Eye Disease
2天前
已完结
Non-uniform signal pooling across the foveola
2个月前
已完结
An eyecare foundation model for clinical assistance: a randomized controlled trial
6个月前
已完结
皖公网安备34019202002308
